XML 21 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue:        
Total revenue $ 42,888 $ 191,566 $ 67,288 $ 215,429
Operating costs and expenses:        
Cost of goods sold $ 3,076 $ 0 $ 4,047 $ 0
Cost, Product and Service [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Research and development $ 61,414 $ 52,008 $ 116,315 $ 102,505
Selling, general and administrative 63,535 26,739 113,138 48,948
Total operating costs and expenses 128,025 78,747 233,500 151,453
Income (loss) from operations (85,137) 112,819 (166,212) 63,976
Interest and other, net        
Interest expense (651) (736) (1,284) (1,507)
Interest income and other, net 644 4,125 3,810 8,303
Total interest and other, net (7) 3,389 2,526 6,796
Income (loss) before income taxes (85,144) 116,208 (163,686) 70,772
Provision for (benefit from) income taxes 169 205 (25) 180
Net income (loss) $ (85,313) $ 116,003 $ (163,661) $ 70,592
Net income (loss) per share:        
Basic $ (0.95) $ 1.34 $ (1.84) $ 0.82
Diluted $ (0.95) $ 1.26 $ (1.84) $ 0.77
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 89,451 86,445 88,835 86,077
Diluted 89,451 91,728 88,835 92,069
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 150,581 $ 0 $ 150,581
Development and Other Revenue [Member]        
Revenue:        
Total revenue 18,957 40,985 38,402 64,848
Product Revenue, Net [Member]        
Revenue:        
Total revenue 15,693 0 20,648 0
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ 8,238 $ 0 $ 8,238 $ 0